Our plants around the world are regularly inspected by health authorities to ensure compliance with the various markets we serve. Following an inspection by the U.S. FDA at our oral finished dose ...

Shield Therapeutics ( (GB:STX) ) has issued an announcement.

Shares of Viatris Inc. VTRS slumped 0.72% to $12.40 Tuesday, on what proved to be an all-around favorable trading session for ...

For pharmaceutical development, this means faster access to life-saving medicines, reduced production costs and a sustainable approach to synthesizing drug candidates. Related Stories ...

Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this ...

Prodose Inc., which also does business as Spirit Pharmaceuticals LLC and is located at 2004-02 Orville Dr. N. in Ronkonkoma, plans to close the local operation on Feb. 24, laying off its total ...

In a comprehensive Genomic Press Interview with researchers from Emory University, a new study published today reveals complex attitudes toward psychedelic therapy, with detailed statistics ...

changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not ...

Viatris (VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus, or SLE. The ...

Yunnan Baiyao Group Co. Ltd. A 0.55% ¥107B Tasly Pharmaceutical Group Co. Ltd. A 1.09% ¥21.97B Jiangsu Hengrui Medicine Co. Ltd. A-0.62% ¥293.66B Zhejiang Hisun Pharmaceutical Co. Ltd. A 0.36% ...

Viatris Inc. (NASDAQ:VTRS), a prominent player in the U.S. specialty pharmaceuticals industry with a market capitalization of $15.06 billion, has been navigating a complex landscape of ...

Viatris Inc. (NASDAQ:VTRS) is a healthcare company that offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).